Last edition
News about
Armata Pharmaceuticals Receives FDA Fast Track Designation for AP-SA02 Bacteriophage Therapy
The FDA has granted Fast Track designation to Armata’s AP-SA02 therapy for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA and MRSA infections.
Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research
Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.
Practo Accelerates AI-Led Healthcare Transformation Amid Global Expansion
Practo is scaling AI-powered systems across patient care, clinical intelligence and healthcare navigation, while expanding its global footprint and engineering capabilities.
Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.
Neuland Laboratories partnership with LIR Life Sciences Corp will focus on developing and manufacturing cell-penetrating peptides to support LIR Life’s patch-based GLP-1/GIP obesity treatment platform.
Bayer to Acquire Perfuse Therapeutics to Boost Ophthalmology Pipeline
Bayer to acquire Perfuse Therapeutics, strengthening its ophthalmology pipeline with a potential disease-modifying therapy for glaucoma and diabetic retinopathy.
JNJ-4804 Co-Antibody Shows Promise in Refractory Inflammatory Bowel Disease
Johnson & Johnson (J&J) investigational JNJ-4804 co-antibody shows superior clinical and endoscopic outcomes in refractory Inflammatory Bowel Disease (IBD), supporting phase 3 advancement with dual IL-23 and TNF pathway targeting.
ZYUS Life Sciences Secures Second US Pain Management Patent
ZYUS Life Sciences secures a second US pain management patent, strengthening its IP portfolio and supporting clinical research in chronic pain and neuropathic pain.
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
Tissue Dynamics and Galmed Pharmaceuticals partner to develop a human-centered cardiac fibrosis platform that will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy